Other News To Note

PharmAthene Inc., of Annapolis, Md., presented pharmacokinetic data from its Valortim anthrax anti-toxin program at the 9th Annual ASM Biodefense and Emerging Diseases Research Meeting in Washington. The study was designed to compare the pharmacokinetics of Valortim following a single intravenous injection in nonchallenged cynomolgus macaques (cynos) to that in cynos infected with Bacillus anthracis. Results indicated that healthy animals had approximately a 45-fold increase in Cmax for a 40-fold increase in dose between 1 and 40 mg/kg and an approximately 34-fold increase in area under the curve. Infected animals had approximately a tenfold increase in Cmax for an eightfold increase in dose.